Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase

详细信息    查看全文

• 作者：Idris Raji^a ; Fatima Yadudu^a ; Emily Janeira^e ; Shaghayegh Fathi^a ; Lindsey Szymczak^c ; James Richard Kornacki^c ; Kensei Komatsu^d ; Jian-Dong Li^d ; Milan Mrksich^c ; Adegboyega K. Oyelere^a ; ^b ; ^{aoyelere@gatech.edu}
• 关键词：HDAC ; histone deacetylase ; HDACi ; histone deacetylase inhibitors ; COX ; cyclooxygenases ; NSAIDs ; non-steroidal anti-inflammatory drugs ; AR ; androgen receptor ; ZBG ; zinc binding group ; PGE2 ; prostaglandin E2
• 刊名：Bioorganic & Medicinal Chemistry
• 出版年：2017
• 出版时间：1 February 2017
• 年：2017
• 卷：25
• 期：3
• 页码：1202-1218
• 全文大小：2854 K
• 卷排序：25

文摘

We herein disclose a series of compounds with potent inhibitory activities towards histone deacetylases (HDAC) and cyclooxygenases (COX). These compounds potently inhibited the growth of cancer cell lines consistent with their anti-COX and anti-HDAC activities. While compound 2b showed comparable level of COX-2 selectivity as celecoxib, compound 11b outperformed indomethacin in terms of selectivity towards COX-2 relative to COX-1. An important observation with our lead compounds (2b, 8, 11b, and 17b) is their enhanced cytotoxicity towards androgen dependent prostate cancer cell line (LNCaP) relative to androgen independent prostate cancer cell line (DU-145). Interestingly, compounds 2b and 17b arrested the cell cycle progression of LNCaP in the S-phase, while compound 8 showed a G0/G1 arrest, similar to SAHA. Relative to SAHA, these compounds displayed tumor-selective cytotoxicity as they have low anti-proliferative activity towards healthy cells (VERO); an attribute that makes them attractive candidates for drug development.